HealthMyne’s technology as a radiomics tool to inform clinical decision-making, identify imaging biomarkers and predict tumor response to cancer treatment was validated by Cancer Control, the company announced recently.

“By extracting hundreds of data points about the biology of a tumor or lesion, radiomics delivers the ability to benefit every point of a cancer patient’s journey, from diagnosis to treatment to survival,” HealthMyne CEO Rose Higgins said in a statement. “This published research validates that HealthMyne’s technology offers clinicians, researchers and life sciences companies a powerful new weapon in the battle against cancer.”

According to a release, the study, which included 150 patients, demonstrated that a significant correlation was obtained between measurements (of lesions) conducted by HealthMyne and the radiologists. Also, the platform’s ease-of-use and consistency improved lesion measurement, decreased variability and showed efficiency gains.

The study was featured in the January 2021 issue.